[Status of homocysteine reduction in prevention of cardiovascular diseases. HOPE-2 study (Heart Outcomes Prevention Evaluation)].
Strasser
R H
RH
Herzzentrum Dresden Universitätsklinik, Technische Universität Dresden, Dresden, Deutschland. Ruth.Strasser@mailbox.tu-dresden.de
D002423:Cause of Death; D004359:Drug Therapy, Combination; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D016019:Survival Analysis; D014805:Vitamin B 12 / Q000627:therapeutic use*; D025101:Vitamin B 6 / Q000627:therapeutic use*
D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12